Le Pape, P. | IICIMED

Le Pape, P.

Professeur – Praticien Hospitalier - Responsable de département

Publications

P302

Inorg. Chem., 2025, 64, 16192-16203. 

Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold.


https://doi.org/10.1021/acs.inorgchem.5c02730

P301

J. Med. Mycol. 2025, 101583.

A One Health Perspective on Diutina catenulata: Phenotypic Traits, Stress Sensitivity, and Virulence Across Diverse Isolates.


https://doi.org/10.1016/j.mycmed.2025.101583

P300

RSC Med. Chem. 2025, 16, 3746–3763. 

 Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy


https://doi.org/10.1039/D5MD00257E

P291

Mycoses. 2025, 68, e70085.

Clade Distinction and Tracking of Clonal Spread by Fourier-Transform Infrared Spectroscopy in Multicenter candida (Candidozyma) auris Ourbreak.


https://doi.org/10.1111/myc.70085

P290

ChemMedChem. 2025, 20, e202400862.

Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.


https://doi.org/10.1002/cmdc.202400862

P280

Chem. Biodiversity 2024, e202300563

Chemical Composition, Antifungal, Antioxidant, and Hemolytic Activities of Morrocan Thymus capitatus Essential Oil.


https://doi.org/10.1002/cbdv.202300563

P278

Antimicrob. Agents Chemother. 2024, e0002224.

Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis.


https://doi.org/10.1128/aac.00022-24

P275

Microorganisms 2023, 11, 2837. 

Is the C-terminal domain an effective and selective target for the design of Hsp90 inhibitors against Candida yeast?


https://doi.org/10.3390/microorganisms11122837

P271

J. Med. Chem. 2023.

Discovery of new broad-spectrum anti-infectives for eukaryotic pathogens using boorganometallic chemistry. 


https://doi.org/10.1021/acs.jmedchem.3c01333

P270

J. Fungi 2023, 9, 430.

The mortality attributable to candidemia in C. auris is higher than that in other Candida species: Myth or reality? 


https://doi.org/10.3390/jof9040430

P268

Future Microbiol. 2023, 18, 1225-1233.

Antifungal efficacy of imidazo[1,2-a]pyrazine based thiosemicarbazones and thiazolidinediones against Sporothrix species.


https://doi.org/10.2217/fmb-2023-0044

P258

Future Microbiol. 2022, 17, 1437-1443. 

Otomycosis caused by the cryptic and emerging species Aspergillus sydowii: two case reports.


https://doi.org/10.2217/fmb-2022-0137

P252

Clin. Microbiol. Infect. 2022

Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples.


https://doi.org/10.1016/j.cmi.2022.09.021

P251

Microorganisms. 2022, 10, 938.

Prototheca infections and ecology from a One Health perspective. 


https://doi.org/10.3390/microorganisms10050938

P249

PLoS One 2022

CRISPR-Cas9 approach confirms Calcineurin-responsive zinc finger 1 (Crz1) transcription factor as a promising therapeutic target in echinocandin-resistant Candida glabrata


https://doi.org/10.1371/journal.pone.0265777

P248

Rev. Iberoam. Micol. 2022.

Lethal destructive sinusopathy due to amphotericin B-resistant Aspergillus flavus: A case report. 


https://doi.org/10.1016/j.riam.2022.01.001

P247

Int. J. Antimicrob. Agents. 2022

Head-to-head comparison of CLSI, EUCAST, Etest and Vitek2 results for Candida auris susceptibility testing.


https://doi.org/10.1016/j.ijantimicag.2022.106558

P246

Microorganisms. 2022, 10, 104. 

Impact of TR34/L98H, TR46/Y121F/T289A and TR53 alterations in azole‐resistant Aspergillus fumigatus on sterol composition and modifications after In Vitro exposure to itraconazole and voriconazole.


https://doi.org/10.3390/microorganisms10010104

P245

J. Antimicrob. Chemother. 2022, 77, 585–597. 

Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata.


https://doi.org/10.1093/jac/dkab454

Autres publications scientifiques

PS07

Antimicrob. Agents Chemother. 2022, 66, e0156321.

Highly conserved gsc1 gene of Pneumocystis jirovecii in patients with or without prior exposure to ehinocandins.


https://doi.org/10.1128/AAC.01563-21

PS06

Parasite. 2022, 29.

Selecting a multiplex PCR panel for accurate molecular diagnosis of intestinal protists: a comparative study of Allplex® (Seegene®), G-DiaParaTrio (Diagenode®), and RIDA®GENE (R-Biopharm®) assays and microscopic examination. 


https://doi.org/10.1051/parasite/2022003

Brevets

B18.

Multivalent fucose derivatives for use as a drug.


Demande de brevet européen n° 17 156 368.7 déposée le 15 février 2017.

B17.

Novel fused pyrimidone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents.


PCT WO 2017/021178 A1, 9 février 2017.

B14.

Milieu, dispositif et procédé de test de la sensibilité d'un inoculum de champignons à un agent antifongique.


Université de Nantes FR 2008/0314184.

B10.

Composés en particulier de dérivés urées ou ester de l'acide haloacetamidobenzoïque et leur utilisation pour le traitement de maladies parasitaires.


Brevet européen n° 03 71 22 86 08,  publié en 2006.

B9.

Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.


Brevet US 2004067998 A1 publié le 8 avril 2004.

B8.

Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.


Brevet CN 1473160A publié le 4 février 2004.

B7.

Procédé de détection de la sensibilité des levures aux antifongiques.


Brevet /FR 1 54 056 - A1 2003. 

B6.

New azolyl-substituted indole derivatives and analogs, useful as antifungal and antiparasitic drugs effective e.g. against Candida albicans, Aspergillus fumigatus and Leishmania.


Brevet EP 1322638 publié le 2 juillet 2003.

B5.

Indole derivatives and their use as antifungal and/or antiparasitic agents.


Brevet CA 2 423 151 A1 publié le 21 mars 2003.

B3.

Activité antimicrotubulaire de nouveaux dérivés benzoylurées: activités antiparasitaires.


Fr. Pat. n° 02.01151, 31 Jan. 2002.

B2.

Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.



Brevet PCT WO 02/24685 A1 déposé le 21 septembre 2001, publié le 28 mars 2002.

B1.

Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux dérivés de l'indole à titre de principes actifs d'une telle composition


Brevet FR 2 814 073 - A1 déposé le 21 septembre 2000, publié le 22 mars 2002.

Thèse